Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apogee Therapeutics, Inc. - Common Stock (NQ:APGE)

81.30 -3.24 (-3.83%)
Streaming Delayed Price Updated: 2:01 PM EDT, May 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apogee Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Eli Lilly Shares Slip Despite Positive Eczema Trial Results: Why the Market Reacted Coolly
INDIANAPOLIS – In a move that has left some retail investors scratching their heads, shares of Eli Lilly and Company (NYSE:LLY) have trended lower this week, despite the pharmaceutical giant releasing... 
Via MarketMinute
News headline image
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for Investors ↗
This biotech innovator in immunology reported a notable insider sale as its stock outperformed and drug development efforts continue. 
Via The Motley Fool
Topics Regulatory Compliance
Apogee Therapeutics (NASDAQ:APGE) Reports Q4 2025 Results, Highlights Cash Runway and Key 2026 Clinical Catalysts ↗
Via Chartmill
News headline image
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Small-Cap Resilience: Russell 2000 Surges 3% as Geopolitical Tensions Ease and ‘Risk-On’ Appetite Returns
On March 23, 2026, the small-cap heavy Russell 2000 Index surged by a definitive 3.0%, soundly outperforming the S&P 500 and the Nasdaq Composite in a session characterized by aggressive "risk-on"... 
Via MarketMinute
Topics ETFs Economy Stocks
Gapping stocks in Monday's session ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026
Webcast to be held Monday, March 23rd at 8:00 a.m. ET 
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗
Spyre Therapeutics focuses on antibody therapies for inflammatory bowel disease, advancing a pipeline aimed at gastrointestinal health. 
Via The Motley Fool
News headline image
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗
This ophthalmic biopharma firm develops sustained drug delivery therapies for eye diseases, targeting both U.S. and global markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
VR Adviser Adds Over 1 Million Savara Shares ↗
This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗
Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing ↗
Liquidia develops inhaled and injectable therapies for pulmonary arterial hypertension, targeting unmet needs in the U.S. biopharma market. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million ↗
This biotech specializes in monoclonal antibody therapies for inflammatory and immunological diseases with significant unmet needs. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges ↗
RAPT Therapeutics develops oral therapies for oncology and inflammatory diseases, with lead candidates progressing in clinical trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst ↗
This clinical-stage biotech develops therapies targeting hematologic disorders, with a pipeline centered on red blood cell biology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Great Rotation: Small-Cap Stocks Slay the Giants as Market Breadth Hits Record Highs
NEW YORK — After years of living in the shadow of trillion-dollar tech titans, the "little guys" of the stock market are finally having their day in the sun. As of February 24, 2026, the financial... 
Via MarketMinute
Topics Economy Initial Public Offering
News headline image
Apogee Therapeutics to Participate in Upcoming March Conferences
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million ↗
Praxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗
Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗
Arcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress ↗
Praxis Precision Medicines develops therapies for central nervous system disorders, with candidates targeting depression and epilepsy. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million ↗
This clinical-stage biotech develops monoclonal antibody therapies targeting chronic inflammatory and immunological diseases. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026
From Apogee Therapeutics
Via GlobeNewswire
News headline image
The Great Rotation: Russell 2000’s Historic 15-Day Streak Marks a Seismic Shift in Market Leadership
In a move that has rewritten the record books of Wall Street, the small-cap-heavy Russell 2000 index recently concluded a historic 15-session winning streak of daily outperformance against the S&P 500.... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
What Investors Should Know About a $1.5 Million Apogee Insider Sale Amid a 60% Stock Rally ↗
This clinical-stage biotech focused on long-acting antibody therapies reported a notable insider sale amid ongoing pipeline development. 
Via The Motley Fool
Topics Regulatory Compliance
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.